ReviewNature medicine2018
Learning from bacterial competition in the host to develop antimicrobials.
Review in Nature medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed.
- Metabolic profiling and microbiological evaluation of Staphylococcus aureus in a poly-microbial system in soft white cheese.Scientific reports · 2026Article
- Interfacial Chemistry-Tailored Silica&Metal-Based Heterostructures: from Rational Design to Antibacterial Applications.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Structure-Activity Relationship and Crystallographic Study of New Monobactams.Journal of medicinal chemistry · 2026Article
- Microbial innovations for sustainable construction: improving durability and environmental impact through the collaboration of civil engineering and microbiology.Archives of microbiology · 2026Review
- Bacteriocins fromFrontiers in microbiology · 2026Review
- Emergent collective alignment gives competitive advantage to longer cells during range expansion.Nature communications · 2025Article
- Dual-functional probiotic hydrogel with puerarin integration for microbiota-neuroimmune regulation in antibiotic-free periodontitis therapy.Bioactive materials · 2025Article
- Article
- HEX-1 reduces colitis-driven colorectal cancer via inactivating the prolyl isomerase PIN1 sensitization and remodeling the gut microbiota.Discover oncology · 2025Article
- Microneedle technology for enhanced topical treatment of skin infections.Bioactive materials · 2025Review
- Contrasting recovery of metagenome‑assembled genomes and derived bacterial communities and functional profiles from lizard fecal and cloacal samples.Animal microbiome · 2025Article
- Global biogeography and projection of antimicrobial toxin genes.Microbiome · 2025Article
- Environmental Antimicrobial Resistance: Implications for Food Safety and Public Health.Antibiotics (Basel, Switzerland) · 2024Review
- Emerging roles of antimicrobial peptides in innate immunity, neuronal function, and neurodegeneration.Trends in neurosciences · 2024Review
- Enhancing Antimicrobial Peptide Activity through Modifications of Charge, Hydrophobicity, and Structure.International journal of molecular sciences · 2024Review
- A systematic framework for understanding the microbiome in human health and disease: from basic principles to clinical translation.Signal transduction and targeted therapy · 2024Review
- MLASM: Machine learning based prediction of anticancer small molecules.Molecular diversity · 2024Article
- Silk Sericin and Its Composite Materials with Antibacterial Properties to Enhance Wound Healing: A Review.Biomolecules · 2024Review
- Using metabolic networks to predict cross-feeding and competition interactions between microorganisms.Microbiology spectrum · 2024Article
- Dissecting Gut-Microbial Community Interactions using a Gut Microbiome-on-a-Chip.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, the alarming increase of antibiotic resistance, compounded by the simultaneous decrease in development of new antibiotics, has created serious concerns for public health. Moreover, current antibiotics also target the beneficial commensal microbes (microbiota) that inhabit our body, sometimes with significant health consequences. The answer to the antibiotic crisis thus involves broad, creative efforts to develop new treatments for infectious agents. Here I discuss what can be learned from investigating microbial competition in vivo and how this knowledge can be utilized to devise new narrow-spectrum therapeutics that target bacterial pathogens while minimizing deleterious effects to the microbiota.
Indexed as
Identifiers
30082869What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.